17. Multiple system atrophy
107 clinical trials,   153 drugs   (DrugBank: 48 drugs),   59 drug target genes,   104 drug target pathways

Searched query = "Multiple system atrophy", "MSA-C", "MSA-P", "Olivopontocerebellar atrophy", "OPCA", "Striatonigral degeneration", "Shy-Drager syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-014644-11-AT
(EUCTR)
10/03/201021/10/2009A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) Multiple System Atrophy of the Parkinsonian Subtype
MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy
Trade Name: AZILECT
INN or Proposed INN: Rasagiline
Other descriptive name: Rasagiline mesylate
Teva Pharmaceutical Industries LtdNULLNot RecruitingFemale: yes
Male: yes
140Portugal;Hungary;United Kingdom;Germany;Netherlands;France;Spain;Italy;Austria
2EUCTR2009-014644-11-NL
(EUCTR)
11/02/201029/10/2009A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) Multiple System Atrophy of the Parkinsonian Subtype
MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy
Trade Name: AZILECT
INN or Proposed INN: Rasagiline
Other descriptive name: Rasagiline mesylate
Teva Pharmaceutical Industries LtdNULLNot RecruitingFemale: yes
Male: yes
243Portugal;Hungary;United Kingdom;Germany;Netherlands;France;Spain;Italy;Austria
3EUCTR2009-014644-11-PT
(EUCTR)
05/02/201011/01/2010A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) Multiple System Atrophy of the Parkinsonian Subtype
MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy
Trade Name: AZILECT
INN or Proposed INN: Rasagiline
Other descriptive name: Rasagiline mesylate
Teva Pharmaceutical Industries LtdNULLNot RecruitingFemale: yes
Male: yes
140Hungary;Portugal;United Kingdom;Germany;Netherlands;France;Spain;Italy;Austria
4EUCTR2009-014644-11-IT
(EUCTR)
10/12/200922/12/2009A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) - NDA Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) - ND Multiple System Atrophy of the Parkinsonian subtype (MSA-P)
MedDRA version: 12.1;Level: LLT;Classification code 10064060;Term: Multiple system atrophy
Trade Name: AZILECT
INN or Proposed INN: Rasagiline
Teva Pharmaceutical Industries LtdNULLNot RecruitingFemale: yes
Male: yes
140Portugal;Hungary;United Kingdom;Germany;Netherlands;France;Spain;Italy;Austria
5EUCTR2009-014644-11-DE
(EUCTR)
08/12/200915/09/2009A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) Multiple System Atrophy of the Parkinsonian Subtype
MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy
Trade Name: AZILECT
INN or Proposed INN: Rasagiline
Other descriptive name: Rasagiline mesylate
Teva Pharmaceutical Industries LtdNULLNot RecruitingFemale: yes
Male: yes
140Portugal;France;Hungary;Spain;Austria;Netherlands;Germany;United Kingdom;Italy
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2009-014644-11-HU
(EUCTR)
19/10/200925/09/2009A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) Multiple System Atrophy of the Parkinsonian Subtype
MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy
Trade Name: AZILECT
INN or Proposed INN: Rasagiline
Other descriptive name: Rasagiline mesylate
Teva Pharmaceutical Industries LtdNULLNot RecruitingFemale: yes
Male: yes
140Portugal;Hungary;United Kingdom;Germany;Netherlands;France;Spain;Italy;Austria